ALK-1 Molecule Information
Name:Activin receptor-like kinase 1
Target Synonym:TGF-B superfamily receptor type I;ACVRLK1 ;Activin receptor-like kinase 1;ALK-1;ACVRL1;ALK1;TSR-I;Serine/threonine-protein kinase receptor R3;SKR3
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:2
Lastest Research Phase:Phase ?
ALK-1 Molecule Synonym Name
ALK-1 Molecule Background
Serine/threonine-protein kinase receptor R3 is an enzyme that in humans is encoded by the ALK1 gene. ALK1 is a receptor in the TGF beta signaling pathway. ALK1 protein is a receptor in the TGF beta signaling pathway. It plays an important role in vascular development, remodeling, and pathologic angiogenesis, play a role in stabilizing angiogenic vessels and contribute to resistance to anti-VEGF therapies, ALK1 blockade may represent an effective therapeutic opportunity complementary to the current antiangiogenic modalities in the clinic. Recently, researcher found that, ALK1-Fc inhibited BMP9-mediated Id-1 expression in human umbilical vein endothelial cells and inhibited cord formation by these cells on a Matrigel substrate, in a chick chorioallantoic membrane assay, ALK1-Fc reduced vascular endothelial growth factor-, fibroblast growth factor-, and BMP10-mediated vessel formation, and ALK1-Fc treatment reduced tumor burden in mice receiving orthotopic grafts of MCF7 mammary adenocarcinoma cells.
Ten Dijke P, Ichijo H, et al.,1993, Oncogene 8 (10): 2879¨C87.
Johnson DW, Berg JN, et al., 1996, Nat Genet 13 (2): 189¨C95.
Lawlor MW, Read BP, et al., 2011, Am J Pathol. 178(2):784-93.
Mitchell D,et al., 2010, Mol Cancer Ther.. 9(2):379-88.
ALK-1 Clinical Drug Information
||Renal cell carcinoma, Solid tumours, Multiple myeloma (MM), Hepatocellular carcinoma (HCC), Head and neck cancer
||GT-90001; PF-03446962; PF-3446962; PF-3-446-962
||Pfizer, Duke University Medical Center, Fondazione IRCCS Istituto Nazionale dei Tumori, Suzhou Kintor Pharmaceuticals
||Age-related macular degeneration (AMD), Liver cancer, Cancer